Noetik, an AI-driven biotech firm using self-supervised machine learning and high-throughput spatial data to create cutting-edge cancer therapies, has announced the successful closure of an oversubscribed $40 million Series A funding round.
Noetik, an AI-native biotech company focused on precision cancer therapies, has successfully closed an oversubscribed $40 million Series A financing round. The round was led by Polaris Partners with Managing Partner Amy Schulman joining Noetik’s board of directors. New investors Khosla Ventures, Wittington Ventures, and Breakout Ventures also participated, alongside existing investors DCVC, Zetta Venture Partners, Catalio Capital Management, 11.2 Capital, Epic Ventures, Intermountain Ventures, and North South Ventures. The round was further supported by AI funds ApSTAT Technologies, Linearis Labs, and Ventures Fund, with notable backing from AI pioneer Yoshua Bengio, metabolomics expert David Wishart, Element AI co-founder Jean-François Gagné, and current and former Recursion executives.
The funds will enable Noetik to enhance its spatial omics-based atlas of human cancer biology—one of the largest globally—and expand its high-throughput in vivo CRISPR Perturb-Map platform. The investment will also support the scaling of the company’s multi-modal cancer foundation models, such as OCTO, to advance its pipeline of cancer therapeutics candidates.
Ron Alfa, M.D., Ph.D., CEO and Co-Founder of Noetik, expressed enthusiasm about the investment, stating, “We are thrilled to have the support of incredible investors who share our vision of combining deep patient data and AI to build the future of cancer therapeutics. This funding will accelerate our progress in translating biological insights into therapeutic candidates.”
Founded to tackle challenges in target discovery and biomarker development, Noetik integrates human multimodal spatial omics data with a CRISPR perturbation platform to train self-supervised foundation models for cancer research.
Amy Schulman, Managing Partner at Polaris Partners, commented, “We are excited to partner with Noetik and support their mission to build a pipeline of transformative cancer therapies. Their sophisticated platform and dedicated team have impressed us.”
Noetik aims to establish partnerships with academic institutions, healthcare providers, and pharmaceutical companies. The recent appointment of Shafique Virani, M.D., as Chief Business Officer will spearhead these efforts.
James Hardiman, General Partner at DCVC, added, “Noetik’s rapid development of a sophisticated AI-driven oncology discovery engine in under two years is unprecedented. Their progress and expertise reinforce our commitment to supporting them.”
This Series A funding marks a pivotal milestone for Noetik, solidifying its role as a leader in AI-driven precision oncology and enhancing cancer patient outcomes worldwide.
